The total number of shares and votes in Oasmia Pharmaceutical AB (publ) amounts to 97,858,144 as of December 30, 2014. The increase in the number of shares is attributable to the new share issue with preferential rights for current shareholders carried out in November/December 2014, which comprised 9,785,814 shares. The share issue was registered in its entirety with the Swedish Companies Registration Office on December 15, 2014.

A list of the company principal shareholders will be available at

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, compared to current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. Product development is based on in-house research within nanotechnology and proprietary patents. Oasmia Pharmaceutical AB’s shares, ISIN SE0000722365, are listed on NASDAQ Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX).